Marisa Woutersen

Not the ‘first rodeo’ put in motion by energy drink company, says IPOS | Court’s analysis looked at the meanings of the words, overall appearances, and pronunciation.

The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ’jeopardise collaborative partnerships and hinder innovation.

US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government’s future use of march-in rights.

Patent applications need to offer the full picture when it comes to scientific research, finds Marisa Woutersen at LSPN Europe.

LSPN Europe delved into the challenges of aligning researchers goals with IP and legal frameworks | Disclosure forms, valuing relationships, incentivising researchers and education.

New senior counsel joins IP group from previous roles at a Pittsburgh university, robotics company, and founding own law firm | Experience in patent prosecution in tech for life science sectors.

Italy outerwear brand secures triple victory against TM owner, manufacturer and online store | ‘Dual strategy’ proves fruitful in Hangzhou | Success part of long-term plan to tackle the international trade of counterfeit products.

Biopharmaceutical patent partner leads team of technical advisors and an associate in California | Partner experienced in patent prosecution, freedom-to-operate analysis, and assessing infringement validity in the pharma and biotech industry.

Amy Baker Mandragouras’ (pictured) team follow her from Cooley | New counsel’s scientific expertise is “second-to-none” | Team has experience in strategic counselling and biotech patent portfolios.

Joint study highlights the role of IP rights in attracting investment for startups | EPO’s Deep Tech Finder tool helps investors find startups working on groundbreaking inventions | Finland and France startups most likely to own IP.

New addition brings multi-jurisdiction experience in life sciences and healthcare industries | Significant growth in patent litigation due to complex life sciences disputes and telecom and technology litigation.

Dykema adds senior counsel to IP team - Life Sciences Intellectual Property Review

Court upholds USPTO and the PTAB decisions over blood-oxygen sensor in smartwatches | Ruling finds Masimo patents to be unpatentable and obvious | Only one claim relating to inconsistency to be reversed.

Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

Payments mark the sixth and seventh made to resolve price-fixing charges | Teva donates $50 million in drugs to humanitarian organisations.

Biologics patent attorney aims to strengthen the firm’s global patent networks.

From screens to holograms, Marisa Woutersen explores the growth, challenges and trends of graphical user interface design patent protection.

Discussion will explore the need for effective AI rules in light of risks | UK government’s IP plans may be scrutinised | HoL publishes key report on country’s AI strategy.

Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.

Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.